Multimodality Treatment and Salvage Surgery for the Treatment of Lung Cancer

Simple Summary There is a broad variety of treatment options for lung cancer, which include medical therapy and surgical resection. Opinion varies as to the optimal treatment options and combinations in different contexts of the disease, which has an impact on the prognosis of the disease-relapse and survival. This is a descriptive study on patients who underwent multimodality therapy (a combination of chemotherapy, radiotherapy and surgical resection) and an evaluation of patient and disease characteristics that may have an impact on the treatment pathway. Lung cancer remains the leading cause of cancer deaths in the United Kingdom. For locally advanced disease, multimodality treatment is recommended, which includes a combination of chemotherapy, radiotherapy, surgery and, more recently immunotherapy. Options depend on the resectability of the cancer and there has been debate about the optimal treatment strategy: surgery may be planned to follow chemoradiotherapy (CRT), be offered for residual disease after CRT, or given as salvage therapy for patients treated with CRT who have later relapse of their disease. We conducted a retrospective analysis of all patients who underwent CRT and surgical resection under a single surgical team and performed a descriptive study after dividing the patients into these three groups. For the planned trimodality group, 30-day mortality this was 7% (n = 1) and 1-year survival was 78.6%; the residual disease group had a 30-day mortality rate of 0% and 1-year survival of 81.3%; for the salvage group, the figures were 0% and 62.5%, respectively. The median overall survival of the study population was 35.8 months. Median overall survival in the trimodality group was 35.4 months (20.1-51.7 interquartile range IQR), for the residual group was 34.2 months (18.5-61.0 IQR). and for the salvage group was 35.8 months (32.4-52.7 IQR).)